220355-63-5
| 中文名稱 | 220355-63-5 |
|---|---|
| 中文同義詞 | 化合物 T13251;烏莫司他雜質4;化合物 UKI-1 |
| 英文名稱 | UKI-1 |
| 英文同義詞 | UKI-1;1-Piperazinecarboxylic acid, 4-[(2S)-3-[3-(aminoiminomethyl)phenyl]-1-oxo-2-[[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]amino]propyl]-, ethyl ester;UKI-1C;UKI 1,UKI1;Upamostat Impurity 4 |
| CAS號 | 220355-63-5 |
| 分子式 | C32H47N5O5S |
| 分子量 | 613.81 |
| EINECS號 | |
| 相關類別 | |
| Mol文件 | 220355-63-5.mol |
| 結構式 |  |
220355-63-5 性質
| 沸點 | 745.5±70.0 °C(Predicted) |
|---|---|
| 密度 | 1.23±0.1 g/cm3(Predicted) |
| 儲存條件 | Store at -20°C |
| 溶解度 | 二甲基亞砜：≥28mg/mL（45.62mM） |
| 形態(tài) | 固體 |
| 酸度系數(pKa) | 9.76±0.50(Predicted) |
| 顏色 | 白色至米白色 |
Ki: 0.41 μM (Urokinase-type plasminogen activator (uPA))
Serine protease
UKI-1 (WX-UK1; 0.1-1.0 μg/mL) treatment shows a decrease of tumor cell invasion by up to 50% is achieved in both models with the SCCHN line FaDu and the cervical carcinoma line HeLa.
UKI-1 (WX-UK1) interferes with the plasminogen activation system at 2 levels: it inhibits plasmin formation directly and via inhibition of uPA. In vitro invasion models with highly invasive fibrosarcoma and breast cancer cells showed that UKI-1 effectively inhibits migration of the cells through fibrin matrices.
UKI-1 (WX-UK1) treatment has antimetastatic activities that significantly reduces the number of metastatic lesions and tumor growth in metastasizing rat pancreatic and mammary adenocarcinoma tumor models.
安全信息
| 更新日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2024/11/08 | HY-100415 | 220355-63-5 UKI-1 | 220355-63-5 | 1mg | 1500元 |
| 2024/11/08 | HY-100415 | 220355-63-5 UKI-1 | 220355-63-5 | 5mg | 3500元 |